Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion
Open Access
- 26 March 1999
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 80 (1-2) , 221-228
- https://doi.org/10.1038/sj.bjc.6690506
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Monitoring of bone metastasesEuropean Journal Of Cancer, 1998
- Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone diseaseAnnals of Oncology, 1997
- Markers of bone resorption in patients treated with pamidronateBone, 1995
- Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.Journal of Clinical Endocrinology & Metabolism, 1995
- The effect of calcium supplementation on the circadian rhythm of bone resorption.Journal of Clinical Endocrinology & Metabolism, 1994
- Evaluation of bone disease in breast cancerThe Breast, 1994
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breastEuropean Journal of Cancer and Clinical Oncology, 1988
- Bone metastases and breast cancerCancer Treatment Reviews, 1985
- Calcium excretion (CaE) in metastatic breast cancerBritish Journal of Surgery, 1983